FDA approves cryopreserved ReNeuron formulation

Josh White Sharecast | 19 Jun, 2017 12:54 - Updated: 12:54 | | |

Astrazeneca

ReNeuron Group

1.62

17:18 23/10/17
0.00%
0.00
  • 13,332.90
  • -0.32%-43.00
  • Max: 13,433.09
  • Min: 13,332.90
  • Volume: 0
  • MM 200 : n/a
17:19 23/10/17
  • 1,020.35
  • 0.00%0.02
  • Max: 1,022.54
  • Min: 1,019.90
  • Volume: 0
  • MM 200 : n/a
17:19 23/10/17

Cell-based therapeutics developer ReNeuron Group updated the marker on its cell therapy development programmes targeting degenerative diseases of the retina on Monday, reporting that the US Food and Drug Administration (FDA) had approved the cryopreserved formulation of its human retinal progenitor cell (hRPC) therapeutic candidate.

The AIM-traded firm said that as a result, it had now started treating patients with the formulation in its ongoing US Phase I/II study clinical trial in retinitis pigmentosa (RP) patients.

It said the new proprietary formulation enabled the hRP cells to be frozen for shipping and storage, and easily thawed at the point of clinical use.

That freeze-thaw modality reportedly provided a “greatly enhanced” shelf life for the product, lower prospective cost of goods and the capability to ship the cells for clinical and commercial application anywhere in the world.

The new hRPC formulation had also facilitated an expansion of ReNeuron's clinical programmes in ophthalmology, the board claimed.

As it had previously announced, the company was set to shortly file an application with the FDA to expand the Phase II element of the ongoing Phase I/II clinical trial in RP from six to 20 patients.

The expanded study was designed to provide the “depth and quality” of data that, if positive, would allow subsequent progression to a Phase II/III pivotal study in the indication.

ReNeuron’s board said it also intended to file an application to start a new US Phase II clinical trial later in the year in patients with cone-rod dystrophy, to be conducted alongside the Phase II part of the ongoing RP clinical trial.

“We are delighted that the FDA has approved the use of the cryopreserved formulation of our hRPC retinal cell therapy candidate in our ongoing clinical development programmes,” said ReNeuron CEO Olav Hellebø.

“This is a further significant milestone for ReNeuron, enabling an expansion of our clinical programmes in ophthalmology as well as providing ReNeuron with a significant commercial advantage in terms of prospective cost of goods and ease of use of a retinal disease therapy.”

More news

17:23 London close: Stocks end little changed despite weak reading on industry

London stocks reversed an earlier small loss to trade slightly higher by the close of trading on Monday despite resilience in the pound against the greenback even after the release of weaker-than-expected data on industrial trends.

16:30 Tuesday preview: Results from Anglo American, Bunzl, St James's Place and Whitbread

Tuesday remains quiet for macroeconomic news but the week's major corporate results kick in with updates from Anglo American, Bunzl, St James's Place and Whitbread.

15:50 FTSE 250 movers: Spire surges as it rejects Mediclinic offer; IWG hit by downgrade

London’s FTSE 250 was down 0.2% to 20,109.57 in afternoon trade on Monday.

15:47 FTSE 100 movers: GKN rallies but Mediclinic drops as Spire rejects offer

London’s FTSE 100 was up 0.1% to 7,529.60 in afternoon trade on Monday.

15:33 US open: Stocks pause at record highs

Wall Street was trading on a mixed note in the early going on Monday, albeit after record closes during the previous session with sentiment underpinned by optimism over Trump’s tax plans as investors look ahead to more earnings releases.

15:04 Smith & Nephew acquires 'game changing' shoulder surgery technology

Smith & Nephew has agreed to snap up a US developer of a "game changing" surgical technology that helps speed the healing process in rotator cuff shoulder injuries.

15:11 FCA still investigating RBS's GRG over SME issues

The City watchdog has published an interim report into the treatment by Royal Bank of Scotland small business clients, though it said the bank remained under investigation over some unnamed matters that could see further regulatory action.

14:02 Asia report: Japan leads rise as Abe consolidates strength in election

Japanese equities led Asia-Pacific markets mostly higher on Monday as markets welcomed an election win for Shinzo Abe.

13:28 UK household pressures ease, rate hike expectations rise - IHS Markit

Financial pressures eased for UK households in October while rate hike expectations rose, according to the latest survey from IHS/Markit.

13:11 Europe midday: Stocks turn higher as German exporters balance Catalonia angst

European stocks were picking up a little steam after a listless Monday morning, as slippage in the euro benefitted exporters but Spain's issues with Catalonia continued to cause some anxiety.